All‐cause short‐term mortality · people with unexplained recurrent syncope
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
All‐cause mortality up to 30 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
Summary of findings table ‐ Corticosteroids plus standard care probably leads to lower all‐cause mortality up to 30 days compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review
All‐cause mortality at up to day 28 ‐ total · individuals with moderate to severe disease
Summary of findings table ‐ Convalescent plasma showed no clear difference in all‐cause mortality at up to day 28 ‐ total compared with placebo or standard care alone (high certainty).
1 finding from 1 review
All‐cause mortality ‐ not reported · adults undergoing intra‐ and transperitoneal laparoscopic procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality before hospital discharge · preterm infants
Summary of findings table ‐ routine monitoring showed no clear difference in all‐cause mortality before hospital discharge compared with no routine monitoring of gastric residual (low certainty).
1 finding from 1 review
All‐cause mortality up to 120 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
It is very uncertain whether summary of findings table ‐ Corticosteroids plus standard care changes all‐cause mortality up to 120 days compared with standard care (plus/minus placebo) (very low certainty).
1 finding from 1 review
All‐cause mortality at last · people with liver metastases
Summary of Findings Table ‐ Electrocoagulation in combination with… may leads to lower all‐cause mortality at last compared with control (vehicle solution of allopurinol by mouth) (low certainty).
1 finding from 1 review
All‐cause mortality up to 30 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in all‐cause mortality up to 30 days compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).
1 finding from 1 review
All‐cause mortality up to 120 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality up to 120 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
It is very uncertain whether summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) changes all‐cause mortality up to 120 days compared with low‐dose dexamethasone (6 mg to 8 mg) (very low certainty).
1 finding from 1 review
All‐cause mortality at 6 months (subgroup) · severe cardiorespiratory failure and cardiac arrest
Summary of findings table ‐ Extracorporeal membrane oxygenation (ECMO) showed no clear difference in all‐cause mortality: ECPR subgroup compared with conventional care (moderate certainty).
1 finding from 1 review
All‐cause mortality (a cephalosporin (cefotaxime) versus doxycycline) · people with leptospirosis
It is very uncertain whether summary of findings table ‐ Antibiotics changes all‐cause mortality (a cephalosporin (cefotaxime) versus doxycycline) compared with other antibiotics (very low certainty).
1 finding from 1 review
All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality: all ECMO studies · severe cardiorespiratory failure and cardiac arrest
Summary of findings table ‐ Extracorporeal membrane oxygenation (ECMO) probably leads to lower all‐cause mortality: all ECMO studies compared with conventional care (moderate certainty).
1 finding from 1 review
All‐cause mortality: VV ECMO subgroup · severe cardiorespiratory failure and cardiac arrest
Summary of findings table ‐ Extracorporeal membrane oxygenation (ECMO) probably leads to lower all‐cause mortality: VV ECMO subgroup compared with conventional care (moderate certainty).
1 finding from 1 review
All‐cause mortality: VA ECMO subgroup · severe cardiorespiratory failure and cardiac arrest
Summary of findings table ‐ Extracorporeal membrane oxygenation (ECMO) showed no clear difference in all‐cause mortality: VA ECMO subgroup compared with conventional care (low certainty).
1 finding from 1 review
All‐cause mortality (penicillin versus a cephalosporin (cefotaxime or ceftriaxone)) · people with leptospirosis
It is very uncertain whether summary of findings table ‐ Antibiotics changes all‐cause mortality (penicillin versus a cephalosporin (cefotaxime… compared with other antibiotics (very low certainty).
1 finding from 1 review
Death Analysis 1.1 · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
It is very uncertain whether summary of Findings Table ‐ Antithrombin concentrates changes all‐cause mortality ‐ Intention‐to‐treat analysis compared with no antithrombin concentrates (very low certainty).
1 finding from 1 review